Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Breast Cancer

Free Subscription Articles published in Am J Clin Oncol Retrieve available abstracts of 44 articles: HTML format

Single Articles

January 2026
1. AKRAM U, Nadeem ZA, Rehman OU, Raza MA, et al
   Efficacy and Safety of Camrelizumab Combination Therapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
   Am J Clin Oncol. 2026 Jan 26. doi: 10.1097/COC.0000000000001299.
   PubMed     Abstract available
   
   
   
2. QURESHI Z, Jamil A, Wali N, Okobi TJ, et al
   Predictive Value of PIK3CA Mutations for Response to CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
   Am J Clin Oncol. 2026 Jan 6. doi: 10.1097/COC.0000000000001294.
   PubMed     Abstract available
   
   
   
3. LOTZ M, Keates S, Carr D, Noor N, et al
   Overactive Bladder Symptoms in Cancer Patients Undergoing Chemotherapy.
   Am J Clin Oncol. 2026;49:25-29.
   PubMed     Abstract available
   
   
   December 2025
4. QURESHI Z, Jamil A, Samsuddoha K, Kahlon N, et al
   Dual Inhibition of HER2 and VEGF Pathways in Breast Cancer: A Meta-analysis of Outcomes.
   Am J Clin Oncol. 2025 Dec 29. doi: 10.1097/COC.0000000000001293.
   PubMed     Abstract available
   
   
   
5. QURESHI Z, Jamil A, Kahlon N, Hameed F, et al
   Targeted and Chemo-Free Approaches in HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis.
   Am J Clin Oncol. 2025 Dec 9. doi: 10.1097/COC.0000000000001285.
   PubMed     Abstract available
   
   
   
6. DRANITSARIS G, Neuhalfen H, Seifter N, Peevyhouse A, et al
   Disparities in Biopsy Practice in Metastatic Breast Cancer Patients Managed in Community Oncology Practices in the United States: Implications for Guideline-Concordant Care.
   Am J Clin Oncol. 2025 Dec 4. doi: 10.1097/COC.0000000000001281.
   PubMed     Abstract available
   
   
   October 2025
7. MCCLELLAND S 3RD, Burnette U, Onyewadume L, Smith TK, et al
   Impact of Patient Navigation on Radiation Therapy Completion in Black Breast Cancer Patients: Early Phase I Trial Results From the Navigator-Assisted Hypofractionation (NAVAH) Program.
   Am J Clin Oncol. 2025 Oct 15. doi: 10.1097/COC.0000000000001257.
   PubMed     Abstract available
   
   
   
8. HUANG Y, Ye D, Hassan F, Hart MJ, et al
   Efficacy and Safety of Antibody Drug Conjugates in Previously Treated Hormone Receptor Positive HER2 Negative (or Low) Metastatic Breast Cancer-A Systematic Review and Meta-Analysis.
   Am J Clin Oncol. 2025 Oct 14. doi: 10.1097/COC.0000000000001259.
   PubMed     Abstract available
   
   
   September 2025
9. SHEMBESH RH, Beshr MS, Elhadi M
   Letter to Editor on Qureshi et al. Efficacy and Safety of Abemaciclib in Combination with Endocrine Therapy for HR+/HER2- Advanced or Metastatic Breast Cancer a Systematic Review and Meta-Analysis, Am J Clin Oncol, 2025, 48(1).
   Am J Clin Oncol. 2025;48:477-478.
   PubMed    
   
   
   August 2025
10. EL FAKIH A, Loap P, Cabel L, Allali S, et al
    Real-world Safety of Concurrent Pembrolizumab and Radiotherapy in Triple-negative Breast Cancer.
    Am J Clin Oncol. 2025 Aug 8. doi: 10.1097/COC.0000000000001236.
    PubMed     Abstract available
    
    
    
11. JAIN D, Upreti K, Tak TK, Date SS, et al
    Predicting and Optimizing Synergistic Drug Combinations for Breast Cancer Treatment Using Machine Learning.
    Am J Clin Oncol. 2025 Aug 6. doi: 10.1097/COC.0000000000001244.
    PubMed     Abstract available
    
    
    
12. TALEB I, Witmeyer S, Charitansky H, Auriol S, et al
    Adenoid Cystic Carcinoma of the Breast and Adjuvant Radiation Therapy: A Review of Literature.
    Am J Clin Oncol. 2025;48:392-398.
    PubMed     Abstract available
    
    
    July 2025
13. STEPHENS MJ, Kasliwal N, Burnette UJ, Onyewadume L, et al
    Impact of Chemotherapy on Financial Toxicity in African American Breast Cancer Patients: Early Findings From the Navigator-Assisted Hypofractionation Phase I Clinical Trial.
    Am J Clin Oncol. 2025 Jul 31. doi: 10.1097/COC.0000000000001241.
    PubMed     Abstract available
    
    
    
14. ONYEWADUME L, Burnette U, Flores LE, McClelland S 3rd, et al
    Navigator-Assisted Hypofractionation Program Survey Validation for African American Breast Cancer Patients.
    Am J Clin Oncol. 2025 Jul 31. doi: 10.1097/COC.0000000000001242.
    PubMed    
    
    
    
15. BOUZIANE J, Loap P, Allali S, Escalup L, et al
    Concurrent Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer: Assessing the Efficacy.
    Am J Clin Oncol. 2025 Jul 16. doi: 10.1097/COC.0000000000001237.
    PubMed     Abstract available
    
    
    
16. KARDOKUS K, Stark KA, Lam AB, McClelland S 3rd, et al
    Breast Cancer Patient Treatment Experience at a National Cancer Institute-Designated Cancer Center Before Formal Navigation Integration.
    Am J Clin Oncol. 2025 Jul 14. doi: 10.1097/COC.0000000000001231.
    PubMed     Abstract available
    
    
    
17. ARABSHOMALI A, Goswami S, Masurkar PP
    Inavolisib for HR-Positive, HER2-Negative Advanced Breast Cancer: Clinical Trials and Patient Access Implication.
    Am J Clin Oncol. 2025 Jul 11. doi: 10.1097/COC.0000000000001209.
    PubMed     Abstract available
    
    
    
18. GREGSTON J, Etzold N, Stratemeier N, McClelland S 3rd, et al
    Assessing the Rate and Quality of Breast Cancer Treatment Following Initial Diagnosis.
    Am J Clin Oncol. 2025 Jul 4. doi: 10.1097/COC.0000000000001229.
    PubMed     Abstract available
    
    
    
19. CULBERT MM, Oladeru OT, Brooks ED, Burchianti T, et al
    Empowering Self-advocacy for Breast Health: A Successful Educational Campaign on Breast Cancer Risk and Screening Recommendations.
    Am J Clin Oncol. 2025 Jul 3. doi: 10.1097/COC.0000000000001219.
    PubMed     Abstract available
    
    
    
20. IQBAL H, Juneja B, Chryssofos S, Ahlawat S, et al
    Complications of Implant-Based Reconstruction and Postmastectomy Radiation in the Era of Adjuvant CDK4/6 Inhibitors.
    Am J Clin Oncol. 2025;48:357-361.
    PubMed     Abstract available
    
    
    May 2025
21. MARTORANA F, Sano MV, Fabi A, Paris I, et al
    A Multicenter Real-Life Evaluation of Safety and Effectiveness of the Antibody-Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Am J Clin Oncol. 2025 May 19. doi: 10.1097/COC.0000000000001201.
    PubMed     Abstract available
    
    
    April 2025
22. LOAP P, Chabli S, Cottu P, Kirova Y, et al
    Safety and Tolerability of Concurrent Radiotherapy and Sacituzumab Govitecan in Metastatic Breast Cancer.
    Am J Clin Oncol. 2025 Apr 3. doi: 10.1097/COC.0000000000001195.
    PubMed     Abstract available
    
    
    March 2025
23. ADUWO JY, Burnette UJ, Onyewadume L, Stephens MJ, et al
    Early Cancer Screening Impressions of African-American Breast Cancer Patients Enrolled on the Navigator-Assisted Hypofractionation (NAVAH) Trial.
    Am J Clin Oncol. 2025 Mar 26. doi: 10.1097/COC.0000000000001189.
    PubMed     Abstract available
    
    
    
24. KASLIWAL N, Stephens MJ, Burnette UJ, Onyewadume L, et al
    Navigator-Assisted Hypofractionation (NAVAH) Phase I Clinical Trial of Breast Cancer Patients: Implications for Assessing Personal Versus Familial Financial Toxicity via the Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic I
    Am J Clin Oncol. 2025 Mar 26. doi: 10.1097/COC.0000000000001190.
    PubMed     Abstract available
    
    
    
25. DAVIS KJ, Burnette UJ, Sun Y, Stephens MJ, et al
    Medical Racism and Physician Trust Impressions of African-American Breast Cancer Patients Enrolled on the Navigator-Assisted Hypofractionation (NAVAH) Phase I Clinical Trial.
    Am J Clin Oncol. 2025 Mar 3. doi: 10.1097/COC.0000000000001183.
    PubMed     Abstract available
    
    
    
26. QURESHI Z, Altaf F, Jamil A, Siddique R, et al
    Unlocking the Mysteries of Breast Cancer: The Role of Epigenetics in Diagnosis, Treatment, and Beyond.
    Am J Clin Oncol. 2025 Mar 3. doi: 10.1097/COC.0000000000001177.
    PubMed     Abstract available
    
    
    February 2025
27. CRUTTENDEN J, Grant J, Evans J, Cannon G, et al
    Impact of Consensus Guidelines, Clinical Trials, and COVID-19 on Fractionation Practices for Node-negative Intact Breast Cancer.
    Am J Clin Oncol. 2025 Feb 4. doi: 10.1097/COC.0000000000001167.
    PubMed     Abstract available
    
    
    December 2024
28. SANCHEZ JI, Doose M, Zeruto C, Chollette V, et al
    Assessing the Impact of Multidisciplinary Cancer Consultations on Cancer Quality Metrics.
    Am J Clin Oncol. 2024;47:595-606.
    PubMed     Abstract available
    
    
    
29. BOUZIANE J, Loap P, Cottu P, Escalup L, et al
    Concurrent Use of Radiotherapy and Ribociclib: Preliminary Results and Review of the Literature.
    Am J Clin Oncol. 2024;47:574-579.
    PubMed     Abstract available
    
    
    November 2024
30. CHOI JI, Freedman GM, Guttmann DM, Ahmed K, et al
    Executive Summary of the American Radium Society Appropriate Use Criteria: Regional Nodal Irradiation for Breast Cancer.
    Am J Clin Oncol. 2024 Nov 14. doi: 10.1097/COC.0000000000001154.
    PubMed     Abstract available
    
    
    
31. HASSANZADEH E, Sedighi Pashaki A, Akbari Hamed E, Mehrpooya M, et al
    Evaluating N-acetylcysteine as a Protective Agent Against Chemotherapy-induced Neuropathy in Breast Cancer: A Triple-blind, Randomized Clinical Trial.
    Am J Clin Oncol. 2024 Nov 4. doi: 10.1097/COC.0000000000001153.
    PubMed     Abstract available
    
    
    October 2024
32. LOAP P, Kirova Y
    Assessment of Radiotherapy as a Standalone Treatment Following Neoadjuvant Chemotherapy in Nonmetastatic Breast Cancer: A SEER Database Analysis.
    Am J Clin Oncol. 2024 Oct 4. doi: 10.1097/COC.0000000000001146.
    PubMed     Abstract available
    
    
    September 2024
33. QURESHI Z, Jamil A, Fatima E, Altaf F, et al
    Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2- Advanced or Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Am J Clin Oncol. 2024 Sep 9. doi: 10.1097/COC.0000000000001143.
    PubMed     Abstract available
    
    
    
34. RITTER AR, Prasad RN, Jhawar SR, Bazan JG, et al
    Hypofractionated Radiation Therapy: A Cross-sectional Survey Study of US Radiation Oncologists.
    Am J Clin Oncol. 2024;47:434-438.
    PubMed     Abstract available
    
    
    
35. NAGAI M, Ewbank H, Po SS, Dasari TW, et al
    Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First-in-Human Randomized Pilot Study. Neuromodulation in Cancer Study (NCAN).
    Am J Clin Oncol. 2024;47:425-430.
    PubMed     Abstract available
    
    
    
36. KIM KW, Lopresti M, Graff SL, Witherby S, et al
    Fulfilling the Role of a Parent While Undergoing Treatment for Cancer: A Review of the Literature and the Potential Impact of Childcare Support on Cancer Outcomes.
    Am J Clin Oncol. 2024;47:445-447.
    PubMed     Abstract available
    
    
    July 2024
37. SANCHEZ-FELICIANO A, Onyewadume L, Stephens MJ, Flores LE, et al
    Validation of Spanish-Language Surveys Utilized for the Navigator-Assisted Hypofractionation (NAVAH) Program to Aid Hispanic-American Breast Cancer Patients.
    Am J Clin Oncol. 2024 Jul 26. doi: 10.1097/COC.0000000000001137.
    PubMed     Abstract available
    
    
    
38. BOUZIANE J, Loap P, Cao K, Allali S, et al
    Concurrent Use of Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer: A Single-center Experience and Review of the Literature.
    Am J Clin Oncol. 2024 Jul 16. doi: 10.1097/COC.0000000000001135.
    PubMed     Abstract available
    
    
    
39. PUJARI L, Suresh A, Chowdhury Z, Pradhan S, et al
    Outcomes of De Novo Oligometastatic Breast Cancer Treated With Surgery of Primary and Metastasis Directed Radiotherapy.
    Am J Clin Oncol. 2024 Jul 4. doi: 10.1097/COC.0000000000001129.
    PubMed     Abstract available
    
    
    
40. QURESHI Z, Altaf F, Jamil A, Siddique R, et al
    Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+ and HER2-low Breast Cancer: An Updated Systematic Review and Meta-Analysis of Clinical Trials.
    Am J Clin Oncol. 2024 Jul 2. doi: 10.1097/COC.0000000000001126.
    PubMed     Abstract available
    
    
    June 2024
41. QURESHI Z, Jamil A, Fatima E, Altaf F, et al
    Efficacy of Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Comprehensive Systematic Review and Meta-analysis.
    Am J Clin Oncol. 2024 Jun 21. doi: 10.1097/COC.0000000000001121.
    PubMed     Abstract available
    
    
    
42. QURESHI Z, Jamil A, Altaf F, Siddique R, et al
    Efficacy and Safety of BRCA-targeted Therapy (Polyadenosine Diphosphate-ribose Polymerase Inhibitors) in Treatment of BRCA-mutated Breast Cancer: A Systematic Review and Meta-analysis.
    Am J Clin Oncol. 2024 Jun 20. doi: 10.1097/COC.0000000000001120.
    PubMed     Abstract available
    
    
    April 2024
43. NICHOLSON G, Carlson KB, Hernandez RK, Schenfeld J, et al
    Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018.
    Am J Clin Oncol. 2024;47:177-184.
    PubMed     Abstract available
    
    
    March 2024
44. MISTRY T, Nath A, Pal R, Ghosh S, et al
    Emerging Futuristic Targeted Therapeutics: A Comprising Study Towards a New Era for the Management of TNBC.
    Am J Clin Oncol. 2024;47:132-148.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.